Solasia Pharma
Stage
IPO | IPOTotal Raised
$7.8MDate of IPO
3/23/2017Market Cap
11.61BAbout Solasia Pharma
Solasia Pharma, formerly known as JapanBridge, expedites patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia has Asian rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc and an exclusive license to ZIOPHARM's SP-02 / darinaparsin, in major Asian countries. Solasia is currently conducting a Phase 1 study of darinaparsin in PTCL in Japan and Korea.
Solasia Pharma Headquarter Location
3F, Shiodome Building 1-2-20, Kaigan, Minato-ku,
Tokyo, 105-0022,
Japan
+81 3 6721 8332
Expert Collections containing Solasia Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Solasia Pharma is included in 2 Expert Collections, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Solasia Pharma Patents
Solasia Pharma has filed 5 patents.
The 3 most popular patent topics include:
- Antineoplastic drugs
- Experimental cancer drugs
- Monoclonal antibodies
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/15/2020 | 5/10/2022 | Experimental cancer drugs, Transcription factors, Oncology, Antineoplastic drugs, Monoclonal antibodies | Grant |
Application Date | 10/15/2020 |
|---|---|
Grant Date | 5/10/2022 |
Title | |
Related Topics | Experimental cancer drugs, Transcription factors, Oncology, Antineoplastic drugs, Monoclonal antibodies |
Status | Grant |
Latest Solasia Pharma News
Nov 2, 2021
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”). Darinaparsin is a drug candidate under development by Solasia for rela...
Solasia Pharma Web Traffic
Solasia Pharma Rank
Where is Solasia Pharma's headquarters?
Solasia Pharma's headquarters is located at 3F, Shiodome Building, Tokyo.
What is Solasia Pharma's latest funding round?
Solasia Pharma's latest funding round is IPO.
How much did Solasia Pharma raise?
Solasia Pharma raised a total of $7.8M.
Who are Solasia Pharma's competitors?
Competitors of Solasia Pharma include Ology Bioservices, Adastra Pharmaceuticals, Salix Pharmaceuticals, ANI Pharmaceuticals, Supernus Pharmaceuticals and 11 more.
You May Also Like
Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders
Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.
Greystone Pharmaceuticals is a healthcare company focused on wound technologies.
Zebra Pharmaceuticals offers customized health products through nature and science.
Arriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapy
Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.